Hua Wei, Zhang Shu, Wang Fang-Zheng
Cardiac Arrhythmia Center, Fu Wai Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing 100037, China.
Zhonghua Xin Xue Guan Bing Za Zhi. 2007 Dec;35(12):1096-8.
To observed the clinical efficacy of cardiac resynchronization therapy-defibrillator (CRT-D) in selected patients with chronic heart failure one year after implantation.
Seventeen patients with drug-refractory heart failure received CRT-D implantation (6 patients were implanted with InSync Sentry). The underlying heart diseases were dilated cardiomyopathy in 12 patients and ischemic heart disease in 5 patients. There were 13 patients with a history of ventricular tachycardia/ventricular fibrillation.
CRT-D were successfully implanted in all patients without complication. The mean left ventricular pacing threshold was 1.6 V. The defibrillation threshold was no more than 20 J. During a mean follow-up of 13 months, no death occurred and LV function was improved. The shock induced by ventricular tachycardia was delivered in 5 patients and alarming due to heart failure occurred twice in 1 patient.
The implantation of CRT-D for treating refractory heart failure patients is feasible and safe. The application of CRT-D was associated with an improved cardiac function and a reduced risk of sudden cardiac death.
观察心脏再同步化治疗除颤器（CRT-D）植入一年后在特定慢性心力衰竭患者中的临床疗效。
17例药物难治性心力衰竭患者接受了CRT-D植入（6例植入InSync Sentry）。基础心脏病为扩张型心肌病12例，缺血性心脏病5例。13例有室性心动过速/心室颤动病史。
所有患者均成功植入CRT-D，无并发症。左心室平均起搏阈值为1.6V。除颤阈值不超过20J。平均随访13个月期间，无死亡发生，左心室功能得到改善。5例患者发生了由室性心动过速诱发的电击，1例患者因心力衰竭警报发生两次。
植入CRT-D治疗难治性心力衰竭患者是可行且安全的。CRT-D的应用与心脏功能改善和心脏性猝死风险降低相关。
